Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Physical properties of cyclosporin A-loaded nanostructured lipid carriers

Cyclosporin A가 봉입된 nanostructured lipid carriers의 물리적 특성연구

  • Song, Chung-Kil (Department of pharmaceutics, College of Pharmacy, Seoul National University) ;
  • Chung, Suk-Jae (Department of pharmaceutics, College of Pharmacy, Seoul National University) ;
  • Shim, Chang-Koo (Department of pharmaceutics, College of Pharmacy, Seoul National University) ;
  • Kim, Dae-Duk (Department of pharmaceutics, College of Pharmacy, Seoul National University)
  • Published : 2008.02.21
Download PDF
⟨ Previous Next ⟩

Abstract

Cyclosporin A (CyA), a potent immunosuppressive drug used in allogeneic transplants and autoimmune disease, is a typical water-insoluble drug. Recently, nanoparticle carriers were investigated to improve the intestinal absorption of drugs. In this study, CyA-loaded nanostructured lipid carriers (NLCs) were prepared from a hot o/w emulsion using the high pressure homogenization method. The NLCs were consisted of cationic lipids, solid lipids, liquid lipids (oils), surfactant and stabilizer. Encapsulation efficiency of CyA in NLCs was approximately 71%. The average particle size and zeta potential of NLCs were below 250 nm and above +40 mV, respectively. The morphology of NLCs was confirmed by transmission electron microscopy (TEM) analysis. Compared to the CyA powder, higher in vitro release of CyA from NLCs was observed after burst release within 30 min. Thus, CyA-loaded NLCs could be applied not only for parenteral route but also for gastrointestinal administration, which needs further investigation.

Keywords

References

  1. J.L. Italia, V. Bhardwaj and M.N.V.R. Kumar, Diease, destination, dose and delivery aspects of ciclosporin: the state of the art, Drug Disco. Today, 11, 846-854 (2006) https://doi.org/10.1016/j.drudis.2006.07.015
  2. D. Faulds, K.L. Goa and P. Benfield, Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders, Drugs, 45, 953-1040 (1993) https://doi.org/10.2165/00003495-199345060-00007
  3. N.E. Taylor, A.E. Mark, P. Vallat, R.M. Brunne, B. Testa and W.F. Van Gunteren, Solvent dependent conformation and hydrogen bounding capacity of cyclosporin A: evidence from partition coefficient and molecular dynamics simulations, J. Med. Chem., 36, 3753-3764 (1993)
  4. J.L. Italia, D.K. Bhatt, V. Bhardwaj, K. Tikoo and M.N.V. Ravi Kumar, PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral $^{\circledR}$, J. Control. Release, 119, 197-206 (2007) https://doi.org/10.1016/j.jconrel.2007.02.004
  5. M.H. El-Shabouri, Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A, Int. J. Pharm., 249, 101-108 (2002) https://doi.org/10.1016/S0378-5173(02)00461-1
  6. E. Ugazio, R. Cavalli and M.R. Gasco, Incorporation of cyclosporin A in solid lipid nanoparticles, Int. J. Pharm., 241, 341-344 (2002) https://doi.org/10.1016/S0378-5173(02)00268-5
  7. P.J. Carrigan and T.R. Bates, Biopharmaceutics of drugs administered in lipid-containing dosage forms I: GI absorption of griseofulvin from an oil-in-water emulsion in the rat, J. Pharm. Sci., 62, 1476-1479 (1973) https://doi.org/10.1002/jps.2600620918
  8. J.F. Pinto and R.H. Muller, Pellets as carriers of solid lipid nanoparticles ($SLN^{TM}$) for oral administration of drugs, Pharmazie, 54, 506-509 (1999)
  9. K. Manjunath, V. Venkateswarlu, Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration, J. Drug Target., 14, 632-645 (2006) https://doi.org/10.1080/10611860600888850
  10. M. Radtke and R.H. Müller, NLC-nanostructured lipid carriers: the new generation of lipid drug carriers, New Drugs, 2, 48-52 (2001)
  11. R.H. Muller, M. Radtke and S.A. Wissing, Nanostructured lipid matrices for improved microencapsulation of drugs, Int. J. Pharm., 242, 121-128 (2002) https://doi.org/10.1016/S0378-5173(02)00180-1
  12. L. Hu, X. Tang and F. Cui, Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs, J. Pharm. Pharmacol., 56, 1527-1535 (2004) https://doi.org/10.1211/0022357044959
  13. Q.Y. Xiang, M.T. Wang, F. Chen, T. Gong, Y.L. Jian, Z.R. Zhang and Y. Huang, Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles, Arch. Pharm.Res., 30, 519-525 (2007) https://doi.org/10.1007/BF02980228
  14. Y. Li, K.J. Zhu, J.X. Zhang, H.L. Jiang, J.H. Liu, Y.L. Hao, H. Yasuda, A. Ichimaru and K. Yamamoto, In vitro and in vivo studies of cyclosporin A-loaded microspheres based on copolymers of lactide and epsilon-caprolactone: comparison with conventional PLGA microspheres, Int. J. Pharm., 295, 67-76 (2005) https://doi.org/10.1016/j.ijpharm.2005.01.025
  15. C. Washington, Stability of lipid emulsions for drug delivery, Adv. Drug Deliv. Rev., 20, 131-145 (1996) https://doi.org/10.1016/0169-409X(95)00116-O
  16. K. Jores, W. Mehnert, M. Drechsler, H. Bunjes, C. Johann and K. Mader, Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy, J. Control. Release, 95, 217-227 (2004) https://doi.org/10.1016/j.jconrel.2003.11.012
  17. J.X. Wang, X. Sun and Z.R. Zhang, Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles, Eur. J. Pharm. Biopharm., 54, 285-290 (2002) https://doi.org/10.1016/S0939-6411(02)00083-8
  18. Cyclosporin emulsions, US Patent 5660858 (1997)